



EAHAD
2021

VIRTUAL CONGRESS
3-5 February 2021

OPTIMIZING PROPHYLACTIC MANAGEMENT OF PATIENTS WITH VON WILLEBRAND DISEASE

Supported Symposium
Feb 5th, 2021

18:00-19:00 CET

Chair:

Sophie SUSEN - France

Speakers :

Jerzy WINDYGA - Poland

Giancarlo CASTAMAN - Italy

Sophie SUSEN - France

Your personal data are processing for logistics management of our events. LFB BIOMEDICAMENTS acts as a data controller. As a data subject and within the limits and conditions of the regulation, you have the right to access information, a right to rectification, the right to erasure, a right to restriction of processing and a right to object. For complete information, please visit our internet website lesmedicamentslfb.lfb-agera.com. To exercise your rights you can sent an email at privacy@lfb.fr or a mail to the following address: LFB BIOMEDICAMENTS - Group legal and compliance department - DPO - 3 avenue des Tropiques, BP 40305, 91958 Courtabœuf Cedex. You can also submit a complaint to the local data protection authority.



OPTIMIZING PROPHYLACTIC MANAGEMENT OF PATIENTS WITH VON WILLEBRAND DISEASE

Chair:
Sophie SUSEN - France

PROGRAM

Von Willebrand disease in the elderly:
focus on thrombo-embolic risk
Speaker: Jerzy WINDYGA - Poland

How to manage gastro-intestinal bleeding in a
prophylaxis setting in von Willebrand Disease?
Speaker: Giancarlo CASTAMAN - Italy

Long-term prophylaxis in von Willebrand Disease: Results
from a prospective real-life study
Speaker: Sophie SUSEN - France



LFB BIOMEDICAMENTS

Limited company with a capital of 150 000 000 Euros - 491 371 167 RCS EVERY
3, avenue des Tropiques - BP 40305 - 91958 Courtaboeuf Cedex - France
Phone: +33 (0)1 69 82 70 10 - Fax: +33 (0)1 69 07 19 03
www.groupe-lfb.com